Evidence map›Paper›PMID 25667292›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.

Shao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope and 10 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
179citing papers in PubMed, 4 pooled it
48.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

179 citing papers in PubMed, 4 syntheses or guidelines pooled it, 397 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. HPV-specific treatment trends in oropharyngeal squamous cell carcinoma: a population-based analysis with stage-stratified interaction testing.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

119 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Shao Hui HuangShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Wei XuShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
John WaldronShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Lillian SiuShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Xiaowei ShenShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Li TongShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Jolie RingashShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Andrew BayleyShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
John KimShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Andrew HopeShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
John ChoShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Meredith GiulianiShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Aaron HansenShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Jonathan IrishShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Ralph GilbertShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Patrick GullaneShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Bayardo Perez-OrdonezShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Ilan WeinrebShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Fei-Fei LiuShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.
Brian O'SullivanShao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada. Brian.OSullivan@rmp.uhn.on.ca.
Hanalei Watershed Hui · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo refine stage and prognostic group for human papillomavirus (HPV) -related nonmetastatic (M0) oropharyngeal cancer (OPC).

methodsAll patients with nonmetastatic (M0) p16-confirmed OPC treated with radiotherapy with or without chemotherapy from 2000 to 2010 were included. Overall survival (OS) was compared among TNM stages for patients with HPV-related and HPV-unrelated OPC separately. For HPV-related OPC, recursive partitioning analysis (RPA) derived new RPA stages objectively. Cox regression was used to calculate adjusted hazard ratios (AHRs) to derive AHR stages. The performance of survival prediction of RPA stage and AHR stage was assessed against the current seventh edition TNM stages. Prognostic groups were derived by RPA, combining RPA stage and nonanatomic factors.

resultsThe cohort comprised 573 patients with HPV-related OPC and 237 patients with HPV-unrelated OPC, with a median follow-up of 5.1 years. Lower 5-year OS with higher TNM stage was evident for patients with HPV-unrelated OPC (stage I, II, III, and IV 5-year OS: 70%, 58%, 50%, and 30%, respectively; P = .004) but not for patients with HPV-related OPC (stage I, II, III, and IV 5-year OS: 88%, 78%, 71%, and 74%, respectively; P = .56). RPA divided HPV-related OPC into RPA-I (T1-3N0-2b), RPA-II (T1-3N2c), and RPA-III (T4 or N3; 5-year OS: 82%, 76%, and 54%, respectively; P < .001). AHR also yielded a valid classification, but RPA stage demonstrated better survival prediction. A further RPA (including RPA stage, age, and smoking pack-years [PYs]) derived the following four valid prognostic groups for survival: group I (T1-3N0-N2c_≤ 20 PY), group II (T1-3N0-N2c_> 20 PY), group III (T4 or N3_age ≤ 70), and group IVA (T4 or N3_age > 70; 5-year OS: 89%, 64%, 57%, and 40%, respectively; P < .001).

conclusionAn RPA-based TNM stage grouping (stage I/II/III: T1-3N0-N2b/T1-3N2c/T4 or N3, with M1 as stage IV) is proposed for HPV-related OPC as a result of significantly improved survival prediction compared with the seventh edition TNM, and prognostication is further improved by an RPA-based prognostic grouping within the American Joint Committee on Cancer/Union for International Cancer Control TNM framework for HPV-related OPC.

Indexed as

PapillomaviridaeAgedCarcinomaDisease ProgressionFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingOropharyngeal NeoplasmsPapillomavirus InfectionsPrognosisProportional Hazards ModelsSmoking

Identifiers

PMID25667292
OpenAlexW2117286343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.